Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
DH3YK4
|
|||
Drug Name |
Zimura
|
|||
Synonyms |
ARC-1905
Click to Show/Hide
|
|||
Drug Type |
Oligonucleotide
|
|||
Indication | Macular degeneration [ICD-11: 9B78.3; ICD-10: H35.3; ICD-9: 362.5] | Phase 3 | [1] | |
Company |
Ophthotech Corp
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Complement C5 (CO5) | Target Info | Inhibitor | [2] |
KEGG Pathway | Complement and coagulation cascades | |||
Prion diseases | ||||
Pertussis | ||||
Staphylococcus aureus infection | ||||
Herpes simplex infection | ||||
Systemic lupus erythematosus | ||||
Reactome | Activation of C3 and C5 | |||
Peptide ligand-binding receptors | ||||
G alpha (i) signalling events | ||||
Regulation of Complement cascade | ||||
WikiPathways | Complement Activation, Classical Pathway | |||
Human Complement System | ||||
Spinal Cord Injury | ||||
Allograft Rejection | ||||
GPCR ligand binding | ||||
GPCR downstream signaling | ||||
Complement cascade |
References | Top | |||
---|---|---|---|---|
REF 1 | ClinicalTrials.gov (NCT04435366) A Phase 3 Safety and Efficacy Study of Intravitreal Administration of Zimura (Complement C5 Inhibitor). U.S. National Institutes of Health. | |||
REF 2 | C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration: A Randomized Pivotal Phase 2/3 Trial. Ophthalmology. 2021 Apr;128(4):576-586. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.